15,939 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Xponance Inc.

Xponance Inc. purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 15,939 shares of the company’s stock, valued at approximately $1,742,000.

A number of other large investors have also made changes to their positions in RVTY. Gladius Capital Management LP lifted its position in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after buying an additional 106 shares in the last quarter. CENTRAL TRUST Co purchased a new stake in shares of Revvity during the 4th quarter worth approximately $27,000. ORG Partners LLC purchased a new stake in shares of Revvity during the 4th quarter worth approximately $32,000. JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Revvity during the 4th quarter worth approximately $33,000. Finally, Desjardins Global Asset Management Inc. bought a new position in shares of Revvity during the 4th quarter valued at approximately $37,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Trading Up 2.7 %

Revvity stock opened at $103.49 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $135.67. The company has a market capitalization of $12.78 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 2.63 and a beta of 1.09. The stock has a 50-day moving average price of $104.74 and a 200 day moving average price of $101.49.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.10. The company had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Sell-side analysts anticipate that Revvity, Inc. will post 4.65 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity’s dividend payout ratio (DPR) is presently 5.09%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Stifel Nicolaus boosted their target price on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Barclays increased their target price on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. KeyCorp raised their price target on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Raymond James raised their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Finally, UBS Group downgraded Revvity from a “buy” rating to a “neutral” rating and raised their price objective for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.91.

Insider Activity

In other news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now directly owns 92,801 shares in the company, valued at $9,677,288.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.60% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.